Humulin S (Soluble) (Insulin Human (Rdna))

Humulin S is indicated for the management of diabetes mellitus when insulin therapy is required.

• Type 1 diabetes mellitus in adults, adolescents, and children.
• Type 2 diabetes mellitus when oral agents no longer achieve glycemic targets.
• Use as part of a basal‑bolus insulin regimen to control mealtime glucose excursions.
• Hospital or perioperative settings where rapid insulin action is needed.
• Adjunct therapy during pregnancy (category B) under medical supervision.
• Transition from intravenous insulin infusion to subcutaneous therapy in critical care.

• Humulin S delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑kinase/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby reducing endogenous glucose production. The overall effect is a rapid decline in plasma glucose concentration after subcutaneous administration.

Adverse reactions to Humulin S can vary in frequency and severity; they are categorized as common or serious.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized thickening or loss of subcutaneous fat.
• Transient weight gain due to fluid retention.
• Nausea or abdominal discomfort.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.

Before prescribing Humulin S, clinicians should evaluate several safety considerations to minimize risk.

• Assess renal and hepatic function, as impairment can prolong insulin action.
• Review history of hypoglycemia unawareness or previous severe episodes.
• Adjust dose during pregnancy, lactation, or in pediatric patients under close supervision.
• Monitor for signs of cardiovascular disease, especially in patients with edema or heart failure.
• Avoid use in patients with known hypersensitivity to recombinant human insulin or any excipients.
• Store the product refrigerated and discard after the indicated in‑use period to maintain potency.

Humulin S may interact with other medicines that affect glucose metabolism or insulin pharmacokinetics.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment.
• Co‑administration with sulfonylureas or meglitinides that increase risk of hypoglycemia.

Use with caution

• Beta‑blockers can mask hypoglycemia symptoms; monitor glucose closely.
• Corticosteroids and thiazide diuretics may raise blood glucose, requiring dose titration.
• Oral contraceptives and hormone replacement therapy can alter insulin requirements.
• Alcohol consumption can potentiate insulin effect and cause delayed hypoglycemia.